Based on the Bio-Rad Laboratories Inc stock forecast from 4 analysts, the average analyst target price for Bio-Rad Laboratories Inc is USD 369.63 over the next 12 months. Bio-Rad Laboratories Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Bio-Rad Laboratories Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Bio-Rad Laboratories Inc’s stock price was USD 332.91. Bio-Rad Laboratories Inc’s stock price has changed by +3.93% over the past week, -2.04% over the past month and +7.43% over the last year.
No recent analyst target price found for Bio-Rad Laboratories Inc
No recent average analyst rating found for Bio-Rad Laboratories Inc
Company Overview Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Address: 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 Read Less
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufacture...Read More
N/A
N/A
7,700
N/A
USD
USA
Adjusted Closing Price for Bio-Rad Laboratories Inc (BIO)
Loading...
Unadjusted Closing Price for Bio-Rad Laboratories Inc (BIO)
Loading...
Share Trading Volume for Bio-Rad Laboratories Inc Shares
Loading...
Compare Performance of Bio-Rad Laboratories Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for BIO
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To Bio-Rad Laboratories Inc (Sector: Medical Devices )
Frequently Asked Questions About Bio-Rad Laboratories Inc (BIO) Stock
Based on ratings from 4 analysts Bio-Rad Laboratories Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on BIO's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for BIO is USD 369.63 over the next 12 months. The maximum analyst target price is USD 450 while the minimum anlayst target price is USD 300.
Unfortunately we do not have enough data on BIO's stock to indicate if its overvalued.
The last closing price of BIO's stock was USD 332.91.
The most recent market capitalization for BIO is USD 9.33B.
Based on targets from 4 analysts, the average taret price for BIO is projected at USD 369.63 over the next 12 months.
This means that BIO's stock price may go up by +11.03% over the next 12 months.
We can't find any ETFs which contains Bio-Rad Laboratories Inc's stock.
As per our most recent records Bio-Rad Laboratories Inc has 7,700 Employees.
Sorry we do not have any infomation available on Bio-Rad Laboratories Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bio-Rad Laboratories Inc (BIO) Stock
Based on ratings from 4 analysts Bio-Rad Laboratories Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on BIO's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for BIO is USD 369.63 over the next 12 months. The maximum analyst target price is USD 450 while the minimum anlayst target price is USD 300.
Unfortunately we do not have enough data on BIO's stock to indicate if its overvalued.
The last closing price of BIO's stock was USD 332.91.
The most recent market capitalization for BIO is USD 9.33B.
Based on targets from 4 analysts, the average taret price for BIO is projected at USD 369.63 over the next 12 months.
This means that BIO's stock price may go up by +11.03% over the next 12 months.
We can't find any ETFs which contains Bio-Rad Laboratories Inc's stock.
As per our most recent records Bio-Rad Laboratories Inc has 7,700 Employees.
Sorry we do not have any infomation available on Bio-Rad Laboratories Inc's address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
